N.V. Anisimov - Dr. Sc. (Phys.-Math.), Senior Research Scientist, Faculty of Fundamental Medicine, Lomonosov Moscow State University. E-mail: anisimovnv@mail.ru L.L. Gervits - Senior Research Scientist, A.N. Nesmeyanov Institute of Organoelement Compounds of RAS (Moscow). E-mail: gervits@ineos.ac.ru M.V. Gulyaev - Ph. D. (Phys.-Math.), Research Scientist, Faculty of Fundamental Medicine, Lomonosov Moscow State University. E-mail: mihon-epsilon@yandex.ru D.N. Silachev - Ph. D. (Biol.), Senior Research Scientist, Lomonosov Moscow State University, A.N. Belozersky Institute Of Physico-Chemical Biology. E-mail: proteins@mail.ru D.V. Volkov - Student, Faculty of Physics, Lomonosov Moscow State University. E-mail: mdanf@gmail.com O.S. Pavlova - Student, Faculty of Physics, Lomonosov Moscow State University. E-mail: ofleurp@mail.ru G.M. Yusubalieva - Ph. D. (Med.), Senior Research Scientist, Federal medical research center of psychiatry and narcology of Ministry of Health of RF (Moscow). E-mail: gaukhar@gaukhar.org E.A. Shalamova - Student, I.M. Sechenov First Moscow State Medical University. E-mail: eshal-129@yandex.ru Yu.A. Pirogov - Dr. Sc. (Phys.-Math.), Professor, Faculty of Physics, Lomonosov Moscow State University. E-mail: yupi937@gmail.com A.R. Khokhlov - Academic, Dr. Sc. (Phys.-Math.), Professor, Pro-rector, Lomonosov Moscow State University. E-mail: khokhlov@polly.phys.msu.ru

In this paper we report on the application of NMR to study the effects of perfluorocarbon (PFC) Perftoranum® drug on the body of the animal. This preparation is used in medicine as a base to produce a gas-transport function of blood substitutes and research purposes as a platform technology that can be used in clinical conditions existing for other contrast agents, such as paramagnetic or ferrimagnetic contrast agents. Currently the drug Perftoranum® only allowed for clinical use blood substitute with the gas transmission function on the basis of PFCs aim of this study was to track the dynamics of excretion of the drug from the body of the animal. Previously, the dynamics are identified through biochemical analysis data. NMR methods make it possible to solve the problem of non-invasive manner. First MRI and NMR local, including local, identify the localization of the drug after intravenous injection into the body of the animal. Then NMR spectroscopy of rat whole-body tracks the performance of the main components of excretion Perftoranum® - perfluorodecalin (PFD) and perfluoroparamethylcyclohexylpiperidine (PMCP). The studies were conducted at the medical 0,5 T MRI scanner with a modified proprietary transceiver coil. As used laboratory rat breed animals Wistar - males weighing 250−300 g at doses of 5 to 10 ml was injected intravenously. According to NMR signals were recorded fluorine MRI images, revealing the localization zone of Perftoranum® and images carried by the proton assignment of these bands to the anatomical structures. MRI scanning was performed by multiecho with the pulse sequence parameters: TR / TE = 2000 / 16,6 ms, ETL = 2. Local spectra obtained by the method of the stimulated echo - STEAM (TR / TE / TM = 3000 / 17,4 / 5,2 ms). Effective localizable limited volume cube whose side could be varied to the extent necessary - from 2 to 20 cm. According to the local NMR spectroscopy and MRI revealed accumulation of the drug in the liver and spleen. During the month obser-vation period revealed no significant change in content in the body of the animal PMCP, while the content of PFD changed exponentially with decay time constant for 6 days. The results obtained are in good agreement with the known data of biochemical analysis and NMR and MRI data obtained in the study of other perfluorocarbons.

 

1. Jesu\'s Ruiz-Cabelloa., Barnett B.P., Bottomley P.A., Bulte J.W.M. Fluorine (19F) MRS and MRI in biomedicine // NMR in Biomed. 2011. 24. P. 114−129.
2. Trung D Tran, Shelton D Caruthers, Michael Hughes, John N Marsh, Tillmann Cyrus, Patrick M Winter, Anne M Neubauer, Samuel A Wickline, Gregory M Lanza. Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics // International Journal of Nanomedicine. 2007. 2(4). P. 515−526.
3. Yamanouchi K., Murashima R., Yokoyama K. Determination of perfluorochemicals in organs and body fluids by gas chromatography // Chem. Pharm. Bull. 1975. 23(6). P. 1363−1367.
4. Sklifas AN. Gazokhromatograficheskijj analiz raspredelenija i akkumuljacii PFOS v organakh krys posle krovezameshhenija // V kn. «Perftorirovannye uglerody v biologii i medicine». Pushhino. 1980. S. 112−122.
5. Nelson TR., Newman FD., Schiffer LM., Reith JD., Cameron SL. Fluorinenuclearmagneticresonance: calibrationandsystemoptimization // Magn. Reson. Imaging. 1985. 3(3). P. 267−273.
6. Mangala Srinivas, Luis J Cruz, Fernando Bonetto, Arend Heerschap, Carl G Figdor, I. Jolanda M De Vries. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging // Biomaterials. 2010. 31(27). P. 7070−7077.
7. Maevsky EI., Gervits LL. Perfluorocarbon-based blood substitute - Perftoran. RussianExperience // Suppl. ChimicaOggi. ChemistryToday, FocusonFluorineChemistry. 2008. 26(3). P. 8−11.